Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7204239 in Type 2 Diabetes Mellitus and Overweight or Obesity
NCT07137585Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), obesity and Overweight comparing Placebo with RO7204239 (2 arms). Primary endpoint: M-value in a Hyperinsulinemic Euglycemic Glucose Clamp at 24 weeks. Started Sep 2025; status: active, not recruiting.
02
Drugs
emugrobart
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on NCT07137585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137585.